Rosuvastatin + placebo + aspirin + placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Atherosclerosis
Conditions
Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus
Trial Timeline
Jun 1, 2006 โ Dec 1, 2009
NCT ID
NCT00371501About Rosuvastatin + placebo + aspirin + placebo
Rosuvastatin + placebo + aspirin + placebo is a approved stage product being developed by AstraZeneca for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00371501. Target conditions include Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00371501 | Approved | Completed |
Competing Products
20 competing products in Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 65 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 52 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 77 |
| Micronized 17B-estradiol | Johnson & Johnson | Phase 2/3 | 65 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 85 |
| rosuvastatin + placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Vorapaxar + Placebo + Aspirin + Clopidogrel | Merck | Phase 2 | 52 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| lovastatin | Merck | Phase 2/3 | 65 |
| Ezetimibe + Placebo | Merck | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Niaspan | Merck | Pre-clinical | 23 |
| MK0633 | Merck | Phase 2 | 52 |